Should You Buy DexCom Stock Before Feb. 13?

DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track glucose levels.However, the rising popularity of GLP-1 drugs, which are highly effective in helping people lose weight and also reduce the risk of becoming diabetic, has turned some investors bearish on DexCom's business. If people are slimmer, healthier, and less likely to become diabetic, there would seemingly be less of a need to use CGMs.There's some uncertainty as to how the business will do in the future, and while the stock has struggled over the past year, it has been picking up steam of late, rallying more than 20% in three months. With its latest earnings report coming out on Feb. 13, is it a good idea to buy the healthcare stock before then?Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool